| Filed On | Filing |
|---|---|
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +2 more
Exhibit E – Form of Akron BioManufacturing Release Agreement |
| 02 Nov 2026 | SCHEDULE 13D |
| 15 Oct 2026 | SCHEDULE 13D |
| 14 Oct 2026 |
8-K: Results of Operations and Financial Condition
MaxCyte will host its third quarter 2026 earnings conference call on November 10, 2026 |
| 13 Aug 2026 | 10-Q |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Reports total revenue of $7.3 million for the second quarter of 2026, including $6.5 million of core revenue and $0.8 million of SPL Program-related revenue |
| 04 Aug 2026 | SCHEDULE 13D |
| 29 Jul 2026 | SCHEDULE 13G/A |
| 22 Jun 2026 |
Form 4: Johnston John Joseph, Director
Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy) |
| 22 Jun 2026 |
Form 4: Hemrajani Rekha, Director
Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy) |
| 22 Jun 2026 |
Form 4: Erck Stanley C, Director
Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy) |
| 22 Jun 2026 |
Form 4: Douglas Richard, Director
Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy) |
| 22 Jun 2026 |
Form 4: Collins Cynthia, Director
Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy) |
| 22 Jun 2026 |
Form 4: Brooke William W, Director
Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy) |
| 22 Jun 2026 |
Form 4: Balthrop Patrick J, Director
Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy) |
| 22 Jun 2026 |
Form 4: Al-Wakeel Yasir B., Director
Received 30,421 shares as a grant or award · Granted 49,579 Stock Option (right to buy) |
| 17 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
At the 2026 annual meeting of stockholders of MaxCyte, Inc. (the “Company”) held on June 17, 2026 (the “Annual Meeting”), the Company’s stockholders considered and approved two proposals, each of which is described in more detail in the ... |
| 16 Jun 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
As previously disclosed on a Current Report on Form 8-K filed with the Securities and Exchange Commission on March 20, 2026, on March 16, 2026, MaxCyte, Inc. (the “Company”) received notice from the Listing Qualifications staff of The Na... |
| 14 May 2026 | SCHEDULE 13D |
Loading...